Product Detailed Description

Liposomal Troxerutin 70% — High Bioavailability Vasoprotective Flavonoid Supplement

Product Overview

liposomal Troxerutin 70% is a premium-grade dietary supplement ingredient delivering troxerutin in an advanced liposomal delivery system. Troxerutin (7,3′,4′-tris[O-(2-hydroxyethyl)]rutin) is a semi-synthetic bioflavonoid derived from rutin, a natural flavonoid extracted from the buds of Sophora japonica (Japanese pagoda tree). It belongs to the hydroxyethylrutoside (HR) class of compounds, also known as oxerutins, which are semi-synthetic derivatives of rutin. Troxerutin is chemically characterized as a flavonol, a type of flavonoid, and is more accurately a hydroxyethylrutoside.

Troxerutin has been extensively studied for its vasoprotective, antioxidant, anti-inflammatory, and anti-thrombotic properties. It is clinically established for the treatment of chronic venous insufficiency, varicose syndrome, and capillary fragility. The compound exerts its pharmacological effects through multiple mechanisms, including inhibiting platelet and red blood cell aggregation, improving erythrocyte deformability, protecting endothelial cells, and enhancing microcirculation.

Why Liposomal Technology?

Troxerutin faces significant formulation challenges. The compound exhibits poor oral bioavailability and rapid plasma clearance, limiting its clinical efficacy and requiring high doses to achieve therapeutic effects. Following oral administration, troxerutin is absorbed from the gastrointestinal tract with a time to peak concentration of 1–6 hours, plasma protein binding of approximately 30%, and an elimination half-life of 10–25 hours. Approximately 70% of metabolites are excreted in feces, and enterohepatic circulation may occur.

Liposomal encapsulation provides three critical advantages:

1. Digestive Protection — The phospholipid bilayer shields troxerutin from enzymatic degradation and premature metabolism during digestive transit, preserving its intact molecular structure until reaching optimal absorption sites in the small intestine.

2. Enhanced Cellular Uptake — liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery and bypassing passive diffusion limitations. A comparative pharmacokinetic study demonstrated that an optimized lipid-based delivery system significantly promoted the intestinal absorption of troxerutin in rats, achieving a relative bioavailability of approximately 205.55% compared to control solution.

3. Sustained Release — Liposomal formulations provide controlled release of troxerutin, maintaining consistent active levels for prolonged vasoprotective activity.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% troxerutin by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation protects troxerutin from degradation and enhances intestinal absorption, achieving a relative bioavailability of 205.55% compared to conventional troxerutin solution.

• Vasoprotective Activity — Troxerutin inhibits platelet and red blood cell aggregation, improves erythrocyte deformability, and protects endothelial cells.

• Capillary Protection — Increases capillary resistance and reduces capillary permeability, helping to alleviate edema and venous symptoms.

• Antioxidant Mechanisms — Activates the Nrf2/ARE signaling pathway and enhances antioxidant enzyme activity, protecting cells from oxidative damage.

• Clinically Validated — Clinical trials have demonstrated efficacy in chronic venous insufficiency and varicose syndrome at doses of 470 mg/day and 900 mg/day.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies and commercial pharmaceutical products commonly recommend 300–1,000 mg of troxerutin per day. The standard adult dose for troxerutin oral solution is 1 g per day, administered as a single 10 mL dose or two 5 mL doses. A clinical trial evaluating troxerutin in combination with pycnogenol for venous insufficiency used troxerutin at 470 mg/day for 60 days. Another clinical study used troxerutin at 300 mg three times daily (900 mg/day). For general venous and capillary support, 300–500 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.